Eighty-five percent of diagnosed cases of lung cancer are non-small cell lung cancer (NSCLC). In this group, 5% of patients ...

From new KRAS and HER2 inhibitors to home-administered immunotherapy, recent trials mark a turning point in how metastatic lung cancer is managed.

A panelist discusses how first-line (1L) therapies, including EGFR tyrosine kinase inhibitors (TKIs) such as osimertinib, are the standard of care for treating locally advanced or metastatic ...

This paper explores the potential of mitochondrial-associated programmed-cell-death (mtPCD) patterns as biomarkers for predicting the prognosis of non-small-cell lung cancer (NSCLC). NSCLC is the most ...

they've started making advances on this biological chessboard. But doctors still haven't found their checkmate. While people may still be diagnosed with non-small-cell lung cancer, how they're ...

CAN-2409 extended median overall survival to 24.5 months in NSCLC patients, surpassing standard docetaxel chemotherapy outcomes. The treatment showed a significant survival benefit in non-squamous ...

If you have metastatic non-small-cell lung cancer (NSCLC), you might wonder if the treatment plan that your doctor recommended is the best one for you. Metastatic NSCLC is “stage IV” or ...

Continuous access to radiation treatment is vital for patients with aggressive cancers, such as those with locally advanced non-small cell lung cancer (NSCLC), who require daily treatments to ...

Sugemalimab is already approved for stage 4 NSCLC in Europe and could fill a treatment gap in stage 3 NSCLC. Developed using the OmniRat platform, sugemalimab may reduce immunogenicity and toxicity ...